Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Stock Information for Connect Biopharma Holdings Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Connect Biopharma Holdings Limited

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
Connect Biopharma to Present at Two Upcoming Investor Conferences in June

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.